ICON Public Limited Company (FRA:IJF)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.04B -2.6% |
| Revenue (ttm) | 7.03B +0.8% |
| Net Income | 195.33M -69.0% |
| EPS | 2.47 -67.4% |
| Shares Out | n/a |
| PE Ratio | 46.30 |
| Forward PE | 12.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 117.85 |
| Previous Close | 116.40 |
| Day's Range | 116.40 - 117.85 |
| 52-Week Range | 66.26 - 170.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 22, 2026 |
About FRA:IJF
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient... [Read more]
Financial Performance
In 2025, FRA:IJF's revenue was $8.25 billion, an increase of 0.76% compared to the previous year's $8.19 billion. Earnings were $229.34 million, a decrease of -68.97%.
Financial numbers in USD Financial StatementsNews
Icon price target raised to $164 from $120 at TD Cowen
TD Cowen raised the firm’s price target on Icon (ICLR) to $164 from $120 and keeps a Buy rating on the shares. The firm sees the company’s investigation conclusion as…
Icon price target raised to $125 from $105 at BofA
BofA raised the firm’s price target on Icon (ICLR) to $125 from $105 and keeps an Underperform rating on the shares. Following the Q4 report, the firm believes the company…
Icon price target raised to $159 from $139 at Truist
Truist raised the firm’s price target on Icon (ICLR) to $159 from $139 and keeps a Hold rating on the shares after the company’s Q4 results and initial FY26 outlook.
Icon price target raised to $126 from $123 at RBC Capital
RBC Capital raised the firm’s price target on Icon (ICLR) to $126 from $123 and keeps a Sector Perform rating on the shares. The company’s Q4 earnings and restated financials…
Icon price target raised to $165 from $135 at Jefferies
Jefferies raised the firm’s price target on Icon (ICLR) to $165 from $135 and keeps a Buy rating on the shares. Gross bookings momentum and the accounting investigation outcome were…
Icon price target raised to $160 from $130 at BMO Capital
BMO Capital analyst Sean Dodge raised the firm’s price target on Icon (ICLR) to $160 from $130 and keeps an Outperform rating on the shares. The firm is updating its…
Icon price target raised to $130 from $120 at JPMorgan
JPMorgan raised the firm’s price target on Icon (ICLR) to $130 from $120 and keeps a Neutral rating on the shares post the Q4 report. The company reported strong bookings…
Icon price target raised to $140 from $120 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Icon (ICLR) to $140 from $120 and keeps a Neutral rating on the shares.
Icon price target raised to $168 from $142 at Baird
Baird raised the firm’s price target on Icon (ICLR) to $168 from $142 and keeps an Outperform rating on the shares.
Icon price target raised to $150 from $120 at Barclays
Barclays raised the firm’s price target on Icon (ICLR) to $150 from $120 and keeps an Equal Weight rating on the shares following the fiscal Q4 report. The estimate “reset…
Icon price target raised to $145 from $125 at Leerink
Leerink raised the firm’s price target on Icon (ICLR) to $145 from $125 and keeps a Market Perform rating on the shares.
ICON Public Limited Company Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong commercial performance, improved win rates, and robust bookings, despite revenue recognition issues that led to restatements and a $3.9B backlog adjustment. 2026 guidance anticipates revenue of $7.85B–$8.15B and margin improvement, with continued investment in growth areas and AI.
ICON Public Limited Company Annual report: Q4 2025
ICON Public Limited Company has published its Q4 2025 annual report on May 28, 2026.
ICON Public Limited Company Earnings release: Q4 2025
ICON Public Limited Company released its Q4 2025 earnings on May 28, 2026, summarizing the period's financial results.
ICON Public Limited Company Slides: Q4 2025
ICON Public Limited Company has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on May 28, 2026.
Icon reports Q4 EPS $2.52, consensus $3.12
Reports Q4 revenue $2.11B, consensus $1.99B. CEO, Mr. Barry Balfe commented, “ICON (ICLR) demonstrated continued commercial momentum through the fourth quarter, underpinned by disciplined execution ag...
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation.
Icon price target raised to $105 from $90 at BofA
BofA raised the firm’s price target on Icon (ICLR) to $105 from $90 and keeps an Underperform rating on the shares. The firm is updating its Q4, FY26 and FY27…
ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq
DUBLIN--(BUSINESS WIRE)--ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq.
Icon price target lowered to $120 from $175 at JPMorgan
JPMorgan lowered the firm’s price target on Icon (ICLR) to $120 from $175 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first on…
Icon resumed with a Sector Perform at RBC Capital
RBC Capital analyst Ryan Halsted resumed coverage of Icon (ICLR) with a Sector Perform rating and $123 price target Leading indicators signal a return of clinical trial activity that should…
ICON expands US early phase research capabilities with new clinic and outpatient centres
DUBLIN & SAN ANTONIO--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new,...
HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem
Philadelphia, PA, May 05, 2026 (GLOBE NEWSWIRE) -- HealthVerity, Inc., the leader in privacy-protected real-world data exchange and patient identity solutions, today announced that it has entered into...
ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results
DUBLIN--(BUSINESS WIRE)--ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results.
ICON and Advarra Introduce New ‘Research-Ready,' Connected Site Network Model
DUBLIN & COLUMBIA, Md.--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, and Advarra, the market leader in regulatory reviews and a leading provider of connect...